Medpace Holdings Inc MEDP

Morningstar Rating
$591.29 −2.10 (0.35%)
View Full Chart

Company Report

Narrow-Moat Medpace's Stronger Bookings and Easing Cancellations Support Improved Near-Term Outlook

Medpace is a global late-stage contract research organization, or CRO, that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. The company was founded over 30 years ago in Cincinnati. It is principally based in the US but also operates in Europe, Asia, South America, Africa, and Australia.

Price vs Fair Value

MEDP is trading at a LOCK|$G%QFh< premium.
Price
$591.20
Fair Value
lj>
Uncertainty
LOCK|DT@K
1-Star Price
LOCK|%.DF
5-Star Price
?ns
Economic Moat
LOCK|$&lTq
Capital Allocation
LOCK|?#l$%l

Bulls Say, Bears Say

Bulls

Medpace's small and midsize biopharma customers are very dependent on outsourced clinical trials since they do not have the capacity to run trials in-house.

Bears

Significant pullbacks in biotech funding or declines in outsourcing penetration rates have a material impact on Medpace's growth.

News

Trading Information

Previous Close Price
$593.39
Day Range
$585.00596.00
52-Week Range
$373.00677.90
Bid/Ask
$579.75 / $644.50
Shares Outstanding
27.91M
Market Cap
$16.50B
Volume/Avg
146,430 / 296,250

Key Statistics

Price/Earnings (Normalized)
34.66
Price/Sales
6.13
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
Total Yield
1.81%

Company Profile

Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Growth
Total Number of Employees
6,500

Competitors

Valuation

Metric
MEDP
ICLR
FTRE
Price/Earnings (Normalized)
34.6615.14132.40
Price/Book Value
38.041.363.21
Price/Sales
6.131.530.62
Price/Cash Flow
26.9513.3331.51
Price/Earnings
MEDP
ICLR
FTRE

Financial Strength

Metric
MEDP
ICLR
FTRE
Quick Ratio
0.660.920.85
Current Ratio
0.730.950.96
Interest Coverage
1.530.08
Quick Ratio
MEDP
ICLR
FTRE

Profitability

Metric
MEDP
ICLR
FTRE
Return on Assets (Normalized)
26.82%3.91%2.15%
Return on Equity (Normalized)
130.01%6.87%10.56%
Return on Invested Capital (Normalized)
97.04%6.21%7.32%
Return on Assets
MEDP
ICLR
FTRE

Diagnostics & Research Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
LOCK|xjN<YxCMLOCK|HV$227B
Danaher Corp
DHR
LOCK|!&rvf!^SLOCK|pNS$146B
IQVIA Holdings Inc
IQV
LOCK|$VG&RlLOCK|QqG%$44B
Agilent Technologies Inc
A
LOCK|>H#HtdQLOCK|Rnj$43B
IDEXX Laboratories Inc
IDXX
LOCK|jStFKr>LOCK|$>K$42B
Waters Corp
WAT
LOCK|QvG!t#gLOCK|?m%$40B
Illumina Inc
ILMN
LOCK|t&tZ!b$LOCK|kzL>t$33B
Mettler-Toledo International Inc
MTD
LOCK|k?$t^XsLOCK|#Q#v$27B
Labcorp Holdings Inc
LH
LOCK|^?C!s?>LOCK|d@vs$27B
Quest Diagnostics Inc
DGX
LOCK|nCd>!V%LOCK|%<R%f$26B

Sponsor Center